Methods and reagents for the enhancement of virus transduction in the bladder epithelium

Abstract

Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.

1 - 35 . (canceled) 
     
     
         36 . A method of treating cancer of the bladder comprising: contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent having a structure represented by the chemical formula: 
       
         
           
           
               
               
           
         
         wherein x and y are positive integers; and further contacting the luminal surface of the bladder with a composition comprising a replication competent oncolytic virus. 
       
     
     
         37 . The method of  claim 36 , wherein x is 6 and y is an integer between 8 and 10. 
     
     
         38 . The method of  claim 37 , wherein the pretreatment composition comprises about 0.02 to about 0.5 wt. % of the transduction enhancing agent. 
     
     
         39 . The method of  claim 36 , wherein the oncolytic virus is an oncolytic adenovirus. 
     
     
         40 . The method of  claim 39 , wherein the oncolytic adenovirus is CG8840. 
     
     
         41 . The method of claim  3 , wherein the oncolytic virus composition further comprises a chemotherapeutic agent. 
     
     
         42 . The method of  claim 41 , wherein the chemotherapeutic agent is docetaxel. 
     
     
         43 . The method of  claim 36 , wherein the pretreatment composition further comprises an oxidizing agent. 
     
     
         44 . The method of  claim 43 , wherein the oxidizing agent is selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid. 
     
     
         45 - 71 . (canceled) 
     
     
         72 . The method of  claim 36 , wherein the composition comprising the transduction enhancing agent and the composition comprising the oncolytic virus are co-administered. 
     
     
         73 . The method of  claim 36 , wherein the composition comprising the transduction enhancing agent is administered prior to the composition comprising the oncolytic virus. 
     
     
         74 . The method of  claim 36 , wherein the transduction enhancing agent is polydocanol.